Jacobs Levy Equity Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,356	Closed	-$10.9K	–	1230
2024 Q4	$10.9K	Sell	20,356 -393,913	-95%	-$274K	﹤0.01%	926
2024 Q3	$729K	Buy	414,269 +117,255	+39%	+$164K	﹤0.01%	781
2024 Q2	$348K	Buy	297,014 +254,565	+600%	+$637K	﹤0.01%	878
2024 Q1	$384K	Buy	+42,449	New	+$413K	﹤0.01%	836
2020 Q4	–	Sell	-84,626	Closed	-$1.09M	–	1108
2020 Q3	$1.09M	Buy	84,626 +24,706	+41%	+$213K	0.01%	646
2020 Q2	$609K	Buy	59,920 +40,027	+201%	+$368K	0.01%	757
2020 Q1	$162K	Sell	19,893 -18,349	-48%	-$159K	﹤0.01%	913
2019 Q4	$330K	Buy	+38,242	New	+$215K	﹤0.01%	839

Jacobs Levy Equity Management's MRNS Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 20,356 shares — an estimated $10.9K sold.

Jacobs Levy Equity Management first reported a position in MRNS in Q4 2019 and held it in 8 quarters. The position peaked at $1.09M in Q3 2020. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

Jacobs Levy Equity Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 20,356 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $10.9K.
Jacobs Levy Equity Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2019 and held it in 8 quarters.
Jacobs Levy Equity Management's Marinus Pharmaceuticals, Inc position peaked at $1.09M in Q3 2020.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.